Today, HPTN researchers presented an analysis from HPTN 083 at the 25th International AIDS Conference (AIDS 2024) in Munich. In an open-label extension of HPTN 083, a study among cisgender men and transgender women (TGW) who have sex with men, the clinical utility of RNA viral load testing during follow-up (as part of HIV testing algorithms) was examined in participants on long-acting injectable cabotegravir (CAB-LA). The analysis showed that a single, isolated positive HIV viral load test result, while uncommon, was frequently a false positive result. Repeat HIV viral load testing on a new blood sample can clarify whether the initial positive result indicates actual HIV infection.
About HPTN 083
HPTN 083 is an ongoing Phase 3 study of CAB-LA compared to TDF/FTC among cisgender men and transgender women who have sex with men. HPTN 083 enrolled 4,570 study participants from Argentina, Brazil, Peru, South Africa, Thailand, the United States, and Vietnam. Two-thirds of study participants were under 30 years of age, and 12 percent were transgender women. Half of the participants in the United States identified as Black or African American.
HPTN 083 is co-funded by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases and ViiV Healthcare. ViiV Healthcare and Gilead Sciences, Inc. provided the study product. Three other NIH institutes also collaborated on HPTN 083: the National Institute of Mental Health, the National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Follow us on social media (@HIVptn) for highlights throughout the conference!
Use #AIDS2024 and #PutPeopleFirst to stay connected with other attendees.